WO2007058957A3 - Boroproline compound and cytokine combination therapy - Google Patents

Boroproline compound and cytokine combination therapy Download PDF

Info

Publication number
WO2007058957A3
WO2007058957A3 PCT/US2006/043831 US2006043831W WO2007058957A3 WO 2007058957 A3 WO2007058957 A3 WO 2007058957A3 US 2006043831 W US2006043831 W US 2006043831W WO 2007058957 A3 WO2007058957 A3 WO 2007058957A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
cytokine combination
boroproline
boroproline compound
compound
Prior art date
Application number
PCT/US2006/043831
Other languages
French (fr)
Other versions
WO2007058957A2 (en
Inventor
Margaret J Uprichard
Original Assignee
Point Therapeutics Inc
Margaret J Uprichard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc, Margaret J Uprichard filed Critical Point Therapeutics Inc
Publication of WO2007058957A2 publication Critical patent/WO2007058957A2/en
Publication of WO2007058957A3 publication Critical patent/WO2007058957A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method is provided for treating subjects with boroproline compound and cytokine combination therapy. The invention further provides methods for identifying subjects that are likely to respond to boroproline treatment.
PCT/US2006/043831 2005-11-10 2006-11-09 Boroproline compound and cytokine combination therapy WO2007058957A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US73549105P 2005-11-10 2005-11-10
US60/735,491 2005-11-10
US73571105P 2005-11-11 2005-11-11
US60/735,711 2005-11-11
US80190306P 2006-05-19 2006-05-19
US60/801,903 2006-05-19

Publications (2)

Publication Number Publication Date
WO2007058957A2 WO2007058957A2 (en) 2007-05-24
WO2007058957A3 true WO2007058957A3 (en) 2007-11-15

Family

ID=38049170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043831 WO2007058957A2 (en) 2005-11-10 2006-11-09 Boroproline compound and cytokine combination therapy

Country Status (1)

Country Link
WO (1) WO2007058957A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000619A (en) 2015-07-16 2019-03-06 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation.
AU2018364752A1 (en) * 2017-11-13 2020-05-28 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162436A (en) * 1995-09-13 2000-12-19 Fordham University Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases
US20050084490A1 (en) * 2002-07-09 2005-04-21 Point Therapeutics, Inc. Boroproline compound combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162436A (en) * 1995-09-13 2000-12-19 Fordham University Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases
US20050084490A1 (en) * 2002-07-09 2005-04-21 Point Therapeutics, Inc. Boroproline compound combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAMS ET AL.: "T-cell independent activity of PT-100 against human tumor xenografts in mice", JOURNAL OF IMMUNOTHERAPY, vol. 27, no. 6, November 2004 (2004-11-01), pages S54 *

Also Published As

Publication number Publication date
WO2007058957A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
HK1116202A1 (en) Means and methods for the treatment of tumorous diseases
EP1901727A4 (en) Methods for the treatment of substance abuse and dependence
EP1786515A4 (en) Treatment of the autonomic nervous system
EP1929123A4 (en) Method and apparatus associated with stimulation treatments for wells
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
EP1928466A4 (en) Pdt treatment method for cellulites and cosmetic use
EP1720576A4 (en) Photodynamic therapy for the treatment of acne
EP1814909A4 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
EP1781329A4 (en) Therapy device and related accessories, compositions, and treatment methods
HK1103354A1 (en) Combination therapy for preventing or treating alzheimers disease, and kit therefor
WO2006127900A3 (en) Tl1a in the treatment of disease
EP1819639A4 (en) Nebulizing treatment method
EP1755394A4 (en) Cancer treatment method
EP1879496A4 (en) A device, system and method for determining the effect of photodynamic or photothermal tumor therapy
EP1940515A4 (en) System and method for patient setup for radiotherapy treatment
AU2005316238B2 (en) Cancer treatment method
GB0604471D0 (en) Device and method for the treatment of tumours
WO2009074968A3 (en) Method for predicting the efficacy of cancer therapy
WO2007019312A3 (en) Methods for characterizing and treating cognitive impairment in aging and disease
HK1117780A1 (en) Compounds and methods for the treatment of cancer
IL179359A0 (en) Cancer treatment method
EP1773860A4 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
ZA200709542B (en) Combination therapy in the treatment of cancer
IL175579A0 (en) Epithelium treatment methods and devices for treating the epithelium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837351

Country of ref document: EP

Kind code of ref document: A2